Novartis Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Novartis Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#16 of 15,742 sponsors by registered trial count).
Novartis Pharmaceuticals: 1,375 sponsored US clinical trials, 110 recruiting.
Novartis Pharmaceuticals sponsors 1,375 registered US clinical trials on ClinicalTrials.gov, 110 of them currently recruiting, and 944 completed. 470 of these trials are in Phase 3-4 (later-stage) and 776 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Non-Small Cell Lung Cancer, with 10 trials.
Top-decile sponsor footprint
Novartis Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#16 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
944 of 1,179 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,375 total, page 27 of 28
Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO).
NCT01090323
Terbinafine Compared to Griseofulvin in Children With Tinea Capitis
NCT00117767
A Study of the Clinical Safety, Tolerability, and Efficacy of Zoledronic Acid Compared to an Oral Bisphosphonate
NCT00100555
Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis
NCT00100620
The Use of Zoledronic Acid in Men on Androgen Deprivation Therapy for Prostate Cancer With Preexisting Osteoporosis
NCT00171639
Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes
NCT00099892
Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes
NCT00099853
Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes
NCT00099944
Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes
NCT00099918
Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia
NCT00084071
Switching Osteoporosis Patients Currently on Oral Bisphosphonate to Zoledronic Acid
NCT00097812
Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma
NCT00079937
Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men
NCT00097825
A Clinical Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes
NCT00099905
Non-small Cell Lung Cancer Study US75 (Z-PACT)
NCT00086268
A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease
NCT00088608
Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients
NCT00303329
Pediatric Hypothalamic Obesity
NCT00076362
Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients
NCT00088582
PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00093600
Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
NCT00088595
Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)
NCT00116376
Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer
NCT00073528
A Prostate Cancer Study in Men Undergoing Androgen Deprivation Therapy
NCT00087659
Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis
NCT00076336
Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease
NCT00099242
Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant
NCT00099749
AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme
NCT00107237
Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
NCT00081926
Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification
NCT00124709
Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT00072709
Dose Escalating Study of the Safety and Efficacy of Patupilone, q3w, in Patients With Non-small Cell Lung Cancer
NCT00171834
Study of Oral AEE788 in Adults With Advanced Cancer
NCT00118456
Bisphosphonate Treatment of Osteogenesis Imperfecta
NCT00063479
A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity
NCT01044186
Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant
NCT00099736
Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions
NCT00061750
Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias
NCT00061763
Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions
NCT00067080
The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00063609
A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies
NCT00621244
Freedom Study: Myfortic in Kidney Transplant Patients
NCT00101738
Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584
NCT00052013
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
NCT00056446
STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea
NCT00050635
Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors
NCT01275222
Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
NCT00050011
Pediatric Epilepsy Study
NCT00050947
EPO906 in Carcinoid and Other Neuroendocrine Tumors
NCT00050349
Pediatric Epilepsy Study
NCT00050934
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 326 |
| Phase 2 | 450 |
| Phase 3 | 393 |
| Phase 4 | 77 |
What is open in the Novartis Pharmaceuticals pipeline
110 recruiting of 1,375 indexed (8% open); 944 completed (69%).
Phase mix: 470 late (III/IV) vs 776 early (I/II) (early-phase heavy).
Top condition: Non-Small Cell Lung Cancer (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Novartis Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 1,375 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
Novartis Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,375 trials (± recruiting share)
- GlaxoSmithKline · 1,345 trials · 4% recruiting
- Eli Lilly and Company · 1,341 trials · 9% recruiting
- University of Pennsylvania · 1,423 trials · 14% recruiting
- University of Michigan · 1,327 trials · 13% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Arcutis Biotherapeutics · 8% recruiting · 25 trials
- Medtronic Endovascular · 8% recruiting · 25 trials
- Penumbra · 8% recruiting · 25 trials
- SK Life Science · 8% recruiting · 25 trials
Related
What to do with this Novartis Pharmaceuticals page
1,375 registered trials is a research-attention snapshot, not an endorsement of Novartis Pharmaceuticals or any single study.
- 110 of Novartis Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Non-Small Cell Lung Cancer is the condition Novartis Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Non-Small Cell Lung Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Novartis Pharmaceuticals pipeline card: 1,375 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.